ArticleJournal of endocrinological investigation2014
Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline.
Article in Journal of endocrinological investigation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies.BMC endocrine disorders · 2020Pooled it
- IGF-I levels during standard Lanreotide dose predicts biochemical outcome of high-frequency regimen in acromegaly.Pituitary · 2024Article
- Insights from an Italian Delphi panel: exploring resistance to first-generation somatostatin receptor ligands and guiding second-line medical therapies in acromegaly management.Journal of endocrinological investigation · 2024Article
- Diabetes Mellitus Secondary to Endocrine Diseases: An Update of Diagnostic and Treatment Particularities.International journal of molecular sciences · 2023Review
- Modern approach to resistant acromegaly.Endocrine · 2023Article
- Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports.Biomolecules · 2021Review
- Observational
- Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly.Reviews in endocrine & metabolic disorders · 2019Review
- Pegvisomant in acromegaly: a multicenter real-life study in Argentina.Archives of endocrinology and metabolism · 2019Observational
- Burden of diabetes mellitus in patients with acromegaly treated with second-line pharmacotherapy in Spain.ClinicoEconomics and outcomes research : CEOR · 2019Article
- Article
- Uridine 5'-diphospho-glucronosyltrasferase: Its role in pharmacogenomics and human disease.Experimental and therapeutic medicine · 2018Review
- How to improve effectiveness of pegvisomant treatment in acromegalic patients.Journal of endocrinological investigation · 2018Observational
- Pegvisomant in acromegaly: an update.Journal of endocrinological investigation · 2017Review
- Daily life reflections of acromegaly guidelines.Journal of endocrinological investigation · 2017Article
- Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities.Pituitary · 2017Review
- Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study.European journal of endocrinology · 2015Article
- Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience.Journal of endocrinological investigation · 2015Article
- Optimal use of pegvisomant in acromegaly: are we getting there?Endocrine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.